The Effect of Plasma Lipids and Lipid ‐Lowering Interventions on Bone Mineral Density: A Mendelian Randomization Study

ABSTRACTSeveral epidemiological studies have reported a relationship between statin treatment and increased bone mineral density (BMD) and reduced fracture risk, but the mechanism underlying the purported relationship is unclear. We used Mendelian randomization (MR) to assess whether this relationship is explained by a specific effect in response to statin use or by a general effect of lipid lowering. We utilized 400 single ‐nucleotide polymorphisms (SNPs) robustly associated with plasma lipid levels as exposure. The outcome results were obtained from a heel estimated BMD (eBMD) genomewide association study (GWAS) from the UK Biobank and dual‐energy X‐ray absorptiometry (DXA) BMD at four body sites and fracture G WAS from the GEFOS consortium. We performed univariate and multivariable MR analyses of low‐density lipoprotein cholesterol (LDL‐C), high‐density lipoprotein cholesterol (HDL‐C), and triglyceride levels on BMD and fracture. Univariate MR analyses suggested a causal effect of LDL‐C on eBMD (β = −0.06; standard deviation change in eBMD per standard deviation change in LDL‐C, 95% confidence interval [CI] = –0.08 to −0.04;p = 4  × 10−6), total body BMD (β = −0.05, 95% CI = –0.08 to −0.01,p = 6  × 10−3) and potentially on lumbar spine BMD. Multivariable MR suggested that the effects of LDL ‐C on eBMD and total body BMD were independent of HDL‐C and trigl...
Source: Journal of Bone and Mineral Research - Category: Orthopaedics Authors: Tags: Original Article Source Type: research

Related Links:

AbstractBackgroundBenign paroxysmal positional vertigo (BPPV) is the most common cause of peripheral vertigo and its recurrence is fairly common. Several studies correlated the pathophysiological role of different comorbidities —such as diabetes, osteoporosis, vascular, psychiatric and autoimmune diseases—in the development and recurrence of BPPV. The aim of this study is to analyse the pharmacological history of patients with idiopathic BPPV in relation to the risk of developing recurrence.MethodsData regarding 715 patients aged 12 to 87  years (62.7 ± 14) with non-traumatic BPPV were...
Source: European Archives of Oto-Rhino-Laryngology - Category: ENT & OMF Source Type: research
Authors: Hsieh CY, Sung SF, Huang HK Abstract Introduction: Osteoporosis and subsequent fractures are well-recognized complications of stroke. However, drug treatment strategies for osteoporosis after stroke have been rarely discussed in the current guidelines for the management of stroke or osteoporosis.Areas covered: The authors review the epidemiology, characteristics, pathophysiology, and risk prediction of post-stroke osteoporosis and fractures. Then they provide an overview of existing evidence regarding drug treatment strategies for osteoporosis in stroke patients. They also review the effects on bone minera...
Source: Expert Opinion on Pharmacotherapy - Category: Drugs & Pharmacology Tags: Expert Opin Pharmacother Source Type: research
Abstract Beyond being epiphenomenon of shared epidemiological factors, the integration of osteoporosis (OP) with cardiovascular disease (CVD)- termed "calcification paradox"- reflects a continuum of aberrant cardiometabolic status. The present review provides background knowledge on "calcification paradox", focusing on the endocrine aspect of vasculature orchestrated by the osteoblastic molecular fingerprint of vascular cells, acquired via imbalance among established modulators of mineralization. Osteoprotegerin (OPG)-the well-established osteoprotective cytokine-has recently been shown to exer...
Source: Current Medicinal Chemistry - Category: Chemistry Authors: Tags: Curr Med Chem Source Type: research
In this study, there was no increased risk of adverse outcomes (including muscle aches, liver dysfunction, new onset of diabetes, cancer, and bleeding strokes), even when LDL was lowered to as low as 20 mg/dL. Although statin medications themselves have been linked to side effects, especially at high doses, it appears that extremely low LDL concentrations are not responsible for side effects. In other words, lowering LDL beyond our previous target of 70 mg/dL appears to be not only safe but beneficial, in patients with CVD. The post LDL cholesterol: How low can you (safely) go? appeared first on Harvard Health Blog.
Source: Harvard Health Blog - Category: Consumer Health News Authors: Tags: Drugs and Supplements Health Heart Health Source Type: blogs
First study of its kind to show that although low doses of statins appear protective of bone health, high doses may increase risk for osteoporosis.Medscape Medical News
Source: Medscape Radiology Headlines - Category: Radiology Tags: Diabetes & Endocrinology News Source Type: news
THURSDAY, Oct. 10, 2019 -- There is a dose-dependent relationship between diagnosis of osteoporosis and statin treatment, according to a study published online Sept. 26 in Annals of the Rheumatic Diseases. Michael Leutner, M.D., from Medical...
Source: - Pharma News - Category: Pharmaceuticals Source Type: news
Cholesterol-lowering statin drugs may affect osteoporosis risk, depending on the dose.
Source: NYT Health - Category: Consumer Health News Authors: Tags: Cholesterol Osteoporosis Statins (Cholesterol-Lowering Drugs) Source Type: news
An analysis of health data on 7.9 million people reveals lower rates of osteoporosis among low dose statin users and higher rates among high dose users.
Source: Health News from Medical News Today - Category: Consumer Health News Tags: Statins Source Type: news
We examined human lung tissue from COPD patients and normal control subjects, and found a substantial increase in p16-expressing alveolar cells in COPD patients. Using a transgenic mouse deficient for p16, we demonstrated that lungs of mice lacking p16 were structurally and functionally resistant to CS-induced emphysema due to activation of IGF1/Akt regenerative and protective signaling. Fat Tissue Surrounds Skeletal Muscle to Accelerate Atrophy in Aging and Obesity Researchers her...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
ConclusionsThe characteristics of patients starting oral bisphosphonate therapy have changed over time. Consideration must be given to these time trends when designing studies that examine osteoporosis drug effects.
Source: Osteoporosis International - Category: Orthopaedics Source Type: research
More News: Cholesterol | Epidemiology | Men | Orthopaedics | Osteoporosis | Statin Therapy | Study